Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.

Barile E, Wang S, Das SK, Noberini R, Dahl R, Stebbins JL, Pasquale EB, Fisher PB, Pellecchia M.

ChemMedChem. 2014 Jul;9(7):1403-12. doi: 10.1002/cmdc.201400067. Epub 2014 Mar 26.


Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.

Wang S, Placzek WJ, Stebbins JL, Mitra S, Noberini R, Koolpe M, Zhang Z, Dahl R, Pasquale EB, Pellecchia M.

J Med Chem. 2012 Mar 8;55(5):2427-36. doi: 10.1021/jm201743s. Epub 2012 Feb 27.


Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells.

Wu B, Wang S, De SK, Barile E, Quinn BA, Zharkikh I, Purves A, Stebbins JL, Oshima RG, Fisher PB, Pellecchia M.

Chem Biol. 2015 Jul 23;22(7):876-87. doi: 10.1016/j.chembiol.2015.06.011. Epub 2015 Jul 9.


Targeted delivery of paclitaxel to EphA2-expressing cancer cells.

Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, Wu B, Mitra S, Billet S, Fernandez A, Bhowmick NA, Kitada S, Pasquale EB, Fisher PB, Pellecchia M.

Clin Cancer Res. 2013 Jan 1;19(1):128-37. doi: 10.1158/1078-0432.CCR-12-2654. Epub 2012 Nov 15.


EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.

Patel AR, Chougule M, Singh M.

Pharm Res. 2014 Oct;31(10):2796-809. doi: 10.1007/s11095-014-1377-4. Epub 2014 May 29.


Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy.

Yang HW, Hua MY, Liu HL, Tsai RY, Chuang CK, Chu PC, Wu PY, Chang YH, Chuang HC, Yu KJ, Pang ST.

ACS Nano. 2012 Feb 28;6(2):1795-805. doi: 10.1021/nn2048526. Epub 2012 Jan 24.


Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery.

Pilkington-Miksa M, Arosio D, Battistini L, Belvisi L, De Matteo M, Vasile F, Burreddu P, Carta P, Rassu G, Perego P, Carenini N, Zunino F, De Cesare M, Castiglioni V, Scanziani E, Scolastico C, Casiraghi G, Zanardi F, Manzoni L.

Bioconjug Chem. 2012 Aug 15;23(8):1610-22. doi: 10.1021/bc300164t. Epub 2012 Jul 20.


Structure-activity relationship analysis of peptides targeting the EphA2 receptor.

Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z, Pasquale EB.

Biochemistry. 2010 Aug 10;49(31):6687-95. doi: 10.1021/bi1006223.


Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer.

Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN Jr, de Vere White R, Lam KS, Pan CX.

Int J Nanomedicine. 2012;7:2793-804. doi: 10.2147/IJN.S27734. Epub 2012 Jun 6.


HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors.

Wang X, Li J, Wang Y, Cho KJ, Kim G, Gjyrezi A, Koenig L, Giannakakou P, Shin HJ, Tighiouart M, Nie S, Chen ZG, Shin DM.

ACS Nano. 2009 Oct 27;3(10):3165-74. doi: 10.1021/nn900649v.


Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.

Gao W, Xiang B, Meng TT, Liu F, Qi XR.

Biomaterials. 2013 May;34(16):4137-49. doi: 10.1016/j.biomaterials.2013.02.014. Epub 2013 Mar 1.


An ephrin mimetic peptide that selectively targets the EphA2 receptor.

Koolpe M, Dail M, Pasquale EB.

J Biol Chem. 2002 Dec 6;277(49):46974-9. Epub 2002 Sep 25.


Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.

Yu DH, Lu Q, Xie J, Fang C, Chen HZ.

Biomaterials. 2010 Mar;31(8):2278-92. doi: 10.1016/j.biomaterials.2009.11.047. Epub 2010 Jan 6.


Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π-Π Stacking Stabilized Polymeric Micelles.

Shi Y, van der Meel R, Theek B, Oude Blenke E, Pieters EH, Fens MH, Ehling J, Schiffelers RM, Storm G, van Nostrum CF, Lammers T, Hennink WE.

ACS Nano. 2015;9(4):3740-52. doi: 10.1021/acsnano.5b00929. Epub 2015 Apr 6.


Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.

Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G.

Clin Cancer Res. 2013 Apr 1;19(7):1806-15. doi: 10.1158/1078-0432.CCR-12-2764. Epub 2013 Feb 5.


Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.

Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, Wu W, Shao X, Mao Y, Wei Y, Chen L.

J Control Release. 2010 Jul 1;145(1):17-25. doi: 10.1016/j.jconrel.2010.03.007. Epub 2010 Mar 20.


A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy.

Shan L, Cui S, Du C, Wan S, Qian Z, Achilefu S, Gu Y.

Biomaterials. 2012 Jan;33(1):146-62. doi: 10.1016/j.biomaterials.2011.09.025. Epub 2011 Sep 28.


Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.


Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.

Liu YR, Guan YY, Luan X, Lu Q, Wang C, Liu HJ, Gao YG, Yang SC, Dong X, Chen HZ, Fang C.

Biomaterials. 2015 Feb;42:161-71. doi: 10.1016/j.biomaterials.2014.11.039. Epub 2014 Dec 16.

Items per page

Supplemental Content

Support Center